PD-1T TILs as precision biomarker in NSCLC 59 2 Figure S2. Association of PD-1T TILs with long-term benefit and survival. (A) PD-1T TILs per mm2 in pretreatment samples from patients with disease control at 12 months (DC 12m) (n=12) and PD (n=31) in the training set (n=43) and (B) in the validation set (n=14, n=63). Dashed line indicates a cut-off of 90 PD-1T TILs per mm2. Medians, interquartile ranges and minimum/maximum shown in boxplots, **** P<0.0001 and *** P<0.001 by Mann Whitney U-test. (C) Progression-free survival (PFS) (median 26.1 versus 1.3 months, HR 0.30; 95% CI: 0.16-0.58, *** P<0.001) and (D) overall survival (OS) (median 36.6 versus 6.9 months, HR 0.27; 95% CI: 0.14-0.53, **** P<0.0001) of patients with PD-1T high (≥90 per mm2) (n=16) and PD-1T low (<90 per mm2) (n=27) pretreatment samples in the training set. Tick marks represent data censored at the last time the patient was known to be alive and without disease progression or death. P-value was determined by log-rank test.
RkJQdWJsaXNoZXIy MTk4NDMw